Mantle Cell Lymphoma · Brexucabtagene autoleucel (brexu-cel) CAR-T for r/r MCL — single infusion after lymphodepletion (ZUMA-2)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | aggressive |
|---|---|
| Linked regimen | REG-CAR-T-BREXUCEL-MCL |
| ID | IND-MCL-3L-BREXUCEL-CART |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-MCL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 SRC-ZUMA-2-WANG-2020 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 3L+ CAR-T option for r/r MCL post-cBTKi failure. Ukraine access constraint dominant. Pirtobrutinib bridge during manufacturing window is increasingly standard practice.
Used By
Algorithms
ALGO-MCL-2L- ALGO-MCL-2LALGO-MCL-3L- ALGO-MCL-3L
Indication
IND-MCL-3L-LISOCEL- IND-MCL-3L-LISOCEL